Methodological aspects of minimal residual disease assessment by flow cytometry in acute lymphoblastic leukemia: A french multicenter study

Minimal residual disease (MRD) assessment provides a powerful prognostic factor for therapeutic stratification in acute lymphoblastic leukemia (ALL). Multiparameter flow cytometry (MFC) has the potential for a rapid and sensitive identification of high risk patients. Our group has previously published that MRD levels analyzed by clone specific Ig/TcR‐QPCR and MFC were concordant at a sensitivity of 10−4. Here we report the MFC methodological aspects from this multi‐center experience.

[1]  S. Richards,et al.  Minimal residual disease is a significant predictor of treatment failure in non T‐lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993 , 2010, British journal of haematology.

[2]  L. Picker,et al.  Immunophenotypic analysis of hematogones (B-lymphocyte precursors) in 662 consecutive bone marrow specimens by 4-color flow cytometry. , 2001, Blood.

[3]  J. Gratama,et al.  Flow cytometric differential of leukocyte populations in normal bone marrow: Influence of peripheral blood contamination1 , 2009, Cytometry. Part B, Clinical cytometry.

[4]  G. Basso,et al.  Modulation of antigen expression in B‐cell precursor acute lymphoblastic leukemia during induction therapy is partly transient: Evidence for a drug‐induced regulatory phenomenon. Results of the AIEOP‐BFM‐ALL‐FLOW‐MRD‐Study Group , 2010, Cytometry. Part B, Clinical cytometry.

[5]  D. Campana,et al.  Advances in the immunological monitoring of childhood acute lymphoblastic leukaemia. , 2002, Best practice & research. Clinical haematology.

[6]  G. Schmitz,et al.  Consensus protocol for the flow cytometric immunophenotyping of hematopoietic malignancies. Working Group on Flow Cytometry and Image Analysis. , 1996, Leukemia.

[7]  Elaine Coustan-Smith,et al.  New markers for minimal residual disease detection in acute lymphoblastic leukemia. , 2011, Blood.

[8]  D. Campana,et al.  Detection of residual leukemia with immunologic methods: technical developments and clinical implications. , 1994, Leukemia & lymphoma.

[9]  R. Pieters,et al.  Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 September 2008 , 2010, Leukemia.

[10]  S. Hunger,et al.  Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. , 2008, Blood.

[11]  Michael N Dworzak,et al.  Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. , 2002, Blood.

[12]  H. Cavé,et al.  Dexamethasone (6 mg/m2/day) and prednisolone (60 mg/m2/day) were equally effective as induction therapy for childhood acute lymphoblastic leukemia in the EORTC CLG 58951 randomized trial , 2014, Haematologica.

[13]  Jean Feuillard,et al.  Four‐ and five‐color flow cytometry analysis of leukocyte differentiation pathways in normal bone marrow: A reference document based on a systematic approach by the GTLLF and GEIL , 2009, Cytometry. Part B, Clinical cytometry.

[14]  A J van der Sluijs-Gelling,et al.  Improved flow cytometric detection of minimal residual disease in childhood acute lymphoblastic leukemia , 2013, Leukemia.

[15]  M. Keeney,et al.  Technical issues: flow cytometry and rare event analysis , 2013, International journal of laboratory hematology.

[16]  F. Behm,et al.  Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. , 2000, Blood.

[17]  J. Mazur,et al.  Flow cytometric follow-up of minimal residual disease in bone marrow gives prognostic information in children with acute lymphoblastic leukemia , 2003, Leukemia.

[18]  E. Clappier,et al.  Flow cytometry and IG/TCR quantitative PCR for minimal residual disease quantitation in acute lymphoblastic leukemia: a French multicenter prospective study on behalf of the FRALLE, EORTC and GRAALL , 2013, Leukemia.

[19]  Nitin J. Karandikar,et al.  Stability of leukemia-associated immunophenotypes in precursor B-lymphoblastic leukemia/lymphoma: a single institution experience. , 2007, American journal of clinical pathology.

[20]  D. Campana,et al.  Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia. , 2002, Blood.

[21]  H. Cavé,et al.  Clinical Significance of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia , 1998 .

[22]  C. Haanen,et al.  A method for quantification of peripheral blood admixture in bone marrow aspirates. , 1980, Experimental hematology.

[23]  H. Cavé,et al.  Four-color flow cytometry bypasses limitations of IG/TCR polymerase chain reaction for minimal residual disease detection in certain subsets of children with acute lymphoblastic leukemia. , 2005, Haematologica.

[24]  A. Órfão,et al.  BIOMED-1 Concerted Action report: Flow cytometric characterization of CD7+ cell subsets in normal bone marrow as a basis for the diagnosis and follow-up of T cell acute lymphoblastic leukemia (T-ALL) , 2000, Leukemia.

[25]  J. Cayuela,et al.  Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data , 2007, Leukemia.

[26]  Dario Campana,et al.  Minimal residual disease monitoring in childhood acute lymphoblastic leukemia , 2012, Current opinion in hematology.

[27]  M. Kneba,et al.  Has MRD monitoring superseded other prognostic factors in adult ALL? , 2012, Blood.

[28]  H. Dombret,et al.  Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  J. Cayuela,et al.  Excellent prognosis of late relapses of ETV6/RUNX1-positive childhood acute lymphoblastic leukemia: lessons from the FRALLE 93 protocol , 2012, Haematologica.

[30]  A Orfao,et al.  Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). , 1995, Leukemia.

[31]  M. Loken,et al.  Normalization of bone marrow aspirates for hemodilution in flow cytometric analyses , 2009, Cytometry. Part B, Clinical cytometry.

[32]  E. Paietta.  Proposals for the immunological classification of acute leukemias. , 1995, Leukemia.

[33]  B. Wood,et al.  Immaturity associated antigens are lost during induction for T cell lymphoblastic leukemia: Implications for minimal residual disease detection , 2010, Cytometry. Part B, Clinical cytometry.